Literature DB >> 23450275

What's in the black box of arthritis rehabilitation? A comparison of rehabilitation practice for patients with inflammatory arthritis in northern Europe.

Margreth Grotle1, Mari Klokkerud, Ingvild Kjeken, Ann Bremander, Sofia Hagel, Britta Strömbeck, Kim Hørslev-Petersen, Jorit Meesters, Thea P M Vliet Vlieland, Kåre B Hagen.   

Abstract

BACKGROUND: In evaluating complex interventions, it is a challenge for researchers to provide transparent reporting of the intervention content with sufficient detail and clarity such that effects can be compared across studies or countries.
OBJECTIVE: To describe and compare the content of current rehabilitation for patients with inflammatory arthritis across 4 northern European countries. PATIENTS AND METHODS: A total of 731 patients with inflammatory rheumatic diseases participated in a multicentre, longitudinal observational study carried out in Sweden, The Netherlands, Denmark and Norway. Data on context, structure and process were reported by patients and teams at the different participating study sites according to the Scandinavian Team Arthritis Register-European Team Intiative for Care Research (STAR-ETIC) framework.
RESULTS: Although large similarities were found in the context, there were important differences between the Netherlands and the Scandinavian countries. Regarding structure, there were considerable differences in the length of the rehabilitation period across settings and countries. The most evident differences concerned process variables, especially the type and dosage of individual treatment modalities.
CONCLUSION: The variation in important aspects of arthritis rehabilitation found in the present study underline the need for transparent and standardized description of these variables when comparing effects across settings and countries. A standardized description of current practice can be achieved by the STAR-ETIC framework.

Entities:  

Mesh:

Year:  2013        PMID: 23450275     DOI: 10.2340/16501977-1125

Source DB:  PubMed          Journal:  J Rehabil Med        ISSN: 1650-1977            Impact factor:   2.912


  6 in total

1.  [Trends in rehabilitation of patients with rheumatic diseases in Germany].

Authors:  W Mau; W Beyer; I Ehlebracht-König; J-M Engel; E Genth; W H Jäckel; U Lange; K Thiele
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

Review 2.  Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Lindsay M Bearne; Anne-Marie Byrne; Hannah Segrave; Claire M White
Journal:  Rheumatol Int       Date:  2015-11-12       Impact factor: 2.631

3.  National variation in the composition of rheumatology multidisciplinary teams: a cross-sectional study.

Authors:  Mwidimi Ndosi; Rachel Ferguson; Michael R Backhouse; Lindsay Bearne; Phillip Ainsworth; Alan Roach; Elaine Dennison; Lindsey Cherry
Journal:  Rheumatol Int       Date:  2017-05-27       Impact factor: 2.631

4.  Pre-post changes in main outcomes of medical rehabilitation in Germany: protocol of a systematic review and meta-analysis of individual participant and aggregated data.

Authors:  Michael Schuler; Kathrin Murauer; Stefanie Stangl; Anna Grau; Katharina Gabriel; Lauren Podger; Peter U Heuschmann; Hermann Faller
Journal:  BMJ Open       Date:  2019-06-01       Impact factor: 2.692

Review 5.  Beverages in Rheumatoid Arthritis: What to Prefer or to Avoid.

Authors:  Mrinalini Dey; Maurizio Cutolo; Elena Nikiphorou
Journal:  Nutrients       Date:  2020-10-15       Impact factor: 5.717

6.  A quality indicator set for rehabilitation services for people with rheumatic and musculoskeletal diseases demonstrates adequate responsiveness in a pre-post evaluation.

Authors:  Anne-Lene Sand-Svartrud; Gunnhild Berdal; Maryam Azimi; Ingvild Bø; Turid Nygaard Dager; Siv Grødal Eppeland; Guro Ohldieck Fredheim; Anne Sirnes Hagland; Åse Klokkeide; Anita Dyb Linge; Kjetil Tennebø; Helene Lindtvedt Valaas; Ann Margret Aasvold; Hanne Dagfinrud; Ingvild Kjeken
Journal:  BMC Health Serv Res       Date:  2021-02-20       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.